Patents Assigned to Boehringer Ingelheim International GmbH
  • Publication number: 20230286946
    Abstract: The present invention relates to difluoromethyl-pyridin-2-yl triazoles of general formula (I) which are modulators of GABAA receptors containing the ?5 subunit, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for the manufacture of compounds according to the invention.
    Type: Application
    Filed: August 4, 2021
    Publication date: September 14, 2023
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Florian Montel, Yunhai Cui, Niklas Heine, Oliver Hucke, Radoslaw Lipinski, Stefan Peters, Janus Schreiber Larsen
  • Publication number: 20230277783
    Abstract: A nebulizer for nebulizing a fluid is proposed. The nebulizer includes an indicator device with a rotatable indicator element for counting or indicating a number of actuations performed or still possible with the nebulizer and a rotatable shaft which rotatably drives the indicator element. The indicator device is non-detachably attached to the shaft and/or to an inner part of the nebulizer. The nebulizer may further include a positioning device that keeps the shaft in a defined rotational position and/or blocks the shaft from rotating backwards.
    Type: Application
    Filed: June 30, 2021
    Publication date: September 7, 2023
    Applicant: Boehringer Ingelheim International GmbH
    Inventor: Frank HERRMANN
  • Publication number: 20230265203
    Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same for treating and/or preventing lupus nephritis.
    Type: Application
    Filed: October 7, 2022
    Publication date: August 24, 2023
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Scott Ronald BRODEUR, Thomas B. FREEMAN, Gerald Henry Nabozny, Meera RAMANUJAM, Paul SCHOLL, Juergen STEFFGEN
  • Patent number: 11680096
    Abstract: The disclosure relates to compounds specific for IL23A and TNF-alpha, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: June 20, 2023
    Assignees: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, MACROGENICS, INC.
    Inventors: Rachel Rebecca Barrett, Leslie S. Johnson, Sanjaya Singh, Kathleen Last-Barney, Daw-Tsun Shih, Patricia Giblin, Scott Brodeur, Nelamangala Nagaraja
  • Publication number: 20230183650
    Abstract: The present invention relates to a method for rescue of Vesicular Stomatitis Virus (VSV) from DNA in a HEK293 cell line or a HEK293 cell line adapted to suspension growth comprising (a) providing cells from a HEK293 cell line or a HEK293 cell line adapted to suspension growth in cell culture, (b) transfecting the cells with at least one plasmid, wherein the at least one plasmid comprises (i) an expression cassette comprising a VSV genomic cDNA; (ii) at least one expression cassette encoding VSV nucleoprotein (N) protein, VSV phosphoprotein (P) protein, and VSV large (L) protein; and (iii) an expression cassette encoding SV40 Large T antigen; (c) culturing the transfected cells; and (d) harvesting the cell culture supernatant comprising the rescued VSV.
    Type: Application
    Filed: July 8, 2022
    Publication date: June 15, 2023
    Applicant: Boehringer Ingelheim International GmbH
    Inventor: Tobias Nolden
  • Patent number: 11666590
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: June 6, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Uli Christian Broedl, Odd-Erik Johansen, Eric Williams Mayoux, Nima Soleymanlou, Maximilian von Eynatten, Hans-Juergen Woerle, David Z.I. Cherney, Bruce A. Perkins
  • Patent number: 11661430
    Abstract: The present disclosure provides certain tetrazole derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing the same.
    Type: Grant
    Filed: October 13, 2021
    Date of Patent: May 30, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Florian Paul Christian Binder, Thomas Martin Fleck, Jens Willwacher
  • Patent number: 11661458
    Abstract: Disclosed are antibodies and fragments thereof that target the A-domain of Neuropilin-1 (Nrp1A). Also disclosed are methods of using the anti-Nrp1A antibodies for the treatment of various diseases or disorders.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: May 30, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Nina Zippel, Pankaj Gupta, Fei Han, Sarah Low, Juergen Prestle, Leo Thomas
  • Patent number: 11661427
    Abstract: The present disclosure provides certain tetrazole derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing the same.
    Type: Grant
    Filed: October 13, 2021
    Date of Patent: May 30, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Martin Thomas Fleck, Florian Paul Christian Binder, Jens Willwacher
  • Patent number: 11642476
    Abstract: A nebulizer for a fluid, includes a container containing the fluid; a housing part which can be detached from the nebulizer for replacing the container; an inner part; a retaining element connected with and not detachable from the inner part, where the housing part is releasable fixed to the inner part by the retaining element; a delivery mechanism for dispensing the fluid; a manually depressible actuator member, which is a separate part from the retaining element and acts on the retaining element, and wherein the actuator member is depressed to elastically deform or flex the retaining element to allow detachment of the housing part.
    Type: Grant
    Filed: December 15, 2020
    Date of Patent: May 9, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Jens Besseler, Frank Herrmann, Holger Holakovsky, Herbert Argauer, Josef Gatz, Andreas Gorshoefer
  • Publication number: 20230131522
    Abstract: An injection device, in particular an auto-injector, with a single-use part for dispensing an injection solution has a sensor for acquiring a signal, with which an indicator can be determined, which represents a state or a change in state in a process for dispensing the injection solution with the single-use part. Additionally, the injection device has a reusable part, which is held in a detachable manner by coupling to the single-use part and is coupled via a signal connection, wherein the single-use part has the sensor, and/or wherein the reusable part has a reporting system for detecting the single-use part.
    Type: Application
    Filed: February 25, 2021
    Publication date: April 27, 2023
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Olaf LEBAU, Joerg HEISIEP, Andree JUNG
  • Publication number: 20230131465
    Abstract: The invention relates to 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives of general formula (I) which are agonists of GPR52, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to the 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives of general formula (I) for use as a medicament, pharmaceutical compositions comprising at least a compound of general formula (I) and processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Application
    Filed: September 9, 2022
    Publication date: April 27, 2023
    Applicants: Boehringer Ingelheim International GmbH, Arena Pharmaceuticals, Inc.
    Inventors: Kai Gerlach, Daniela Gavina Berta, Marco Ferrara, Kirsten Gutsche, Ursula Mueller-Vieira, Scott Hobson, Frank Runge, Graeme Semple, Viktor Vintonyak, Yifeng Xiong
  • Publication number: 20230131164
    Abstract: The present invention relates to the identification of a genomic integration site for heterologous polynucleotides in Chinese Hamster Ovary (CHO) cells resulting in high RNA and/or protein production. More specifically it relates to CHO cells comprising at least one heterologous polynucleotide stably integrated into the S100A gene cluster of the CHO genome and to methods for the production of said CHO cells. Further, the invention relates to a method for the production of a protein of interest using said CHO cell and to the use of said CHO cell for producing a protein of interest at high yield. Integration within these specific target regions leads to reliable, stable and high yielding production of an RNA and/or protein of interest, encoded by the heterologous polynucleotide.
    Type: Application
    Filed: December 6, 2022
    Publication date: April 27, 2023
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Markus Mueller, Jochen Schaub, Christian Bernloehr, Jennifer Koenitzer
  • Patent number: 11608343
    Abstract: The present invention relates to new [1,3]diazino[5,4-d]pyrimidines and derivatives of Formula (I) wherein the groups R1, R2, R3 and R4 have the meanings given in the claims and specification, their use as inhibitors of HER2 and its mutants, pharmaceutical compositions which contain such compounds and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: April 6, 2021
    Date of Patent: March 21, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Birgit Wilding, Dietrich Boese, Harald Engelhardt, Julian Fuchs, Ralph Neumueller, Mark Petronczki, Dirk Scharn, Matthias Treu
  • Patent number: 11597903
    Abstract: Methods of protein production in continuous perfusion mammalian cell culture bioreactors are provided. Methods for continuous perfusion culture by allowing cells to self-regulate the rate of addition of perfusion medium to the bioreactor via a pH change are presented. Compositions comprising the perfusion medium as well as the process advantages of using hi-end pH control of perfusion or HIPCOP are also presented.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: March 7, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Gregory Walter Hiller, Matthew Paul Gagnon, Ana Maria Ovalle
  • Patent number: 11583532
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R1 and R2 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: February 21, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thomas Trieselmann, Cedrickx Godbout, Christoph Hoenke, Viktor Vintonyak
  • Patent number: 11578080
    Abstract: This invention relates to thienopyrimidinones and their use as inhibitors of TRPA1 activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of fibrotic diseases, inflammatory and auto-immune diseases and CNS-related diseases.
    Type: Grant
    Filed: September 1, 2021
    Date of Patent: February 14, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Martin Thomas Fleck, Florian Paul Christian Binder, Georg Dahmann, Joerg P. Hehn, Annekatrin Charlotte Heimann, Uta Friederike Lessel, Jens Willwacher
  • Patent number: 11578129
    Abstract: The invention describes anti-cancer therapies comprising using an LRP5 antagonist in combination with an anti-PD1 antibody, each as described herein.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: February 14, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Vittoria Zinzalla, Markus Johann Bauer, Barbara Drobits-Handl
  • Patent number: 11572385
    Abstract: It is disclosed an improved multi-step process for the preparation of a highly concentrated liquid formulation containing biomolecules comprising the steps of (a) a first ultrafiltration UF1; (b) a first diafiltration DF1; (c) a second diafiltration DF2; and (d) a second ultrafiltration UF2; wherein an aqueous solution of one or more salts, as liquid medium B, is used for step (b) and water or an aqueous solution of one or more salts, as liquid medium C, is used for step (c), wherein the one or more salts used for step (b) are the same or different from the one or more salts used for step (c) and wherein the liquid medium B has an ionic strength which is higher than the ionic strength of the liquid medium C. The process according to the present invention allows the preparation of well-defined highly concentrated formulations containing biomolecules, particularly proteins, intended for pharmaceutical or non-pharmaceutical use.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: February 7, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Patrick Garidel, Sven Bahrenburg, Torsten Schultz-Fademrecht, Andrea Eiperle
  • Patent number: RE49446
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R1, R2 and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
    Type: Grant
    Filed: October 14, 2020
    Date of Patent: March 7, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: C├ędrickx Godbout, Thomas Trieselmann, Viktor Vintonyak